Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanzalintinib in advanced solid tumors
NCT03845166Phase 1Active, not recruiting
- Sponsor
- Exelixis, Inc.
- Start
- Mar 2019
- Primary completion
- Aug 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 10
01
Overview
Phase 1, open-label trial of zanzalintinib in solid tumor, clear cell renal cell carcinoma (ccRCC), non-clear cell renal cell carcinoma (nccRCC) and 3 more (5 arms), sponsored by Exelixis, Inc. Primary endpoints: Maximum Tolerated Dose / Recommended Dose up to 24 months, Objective Response Rate up to 24 months and 2 more. Started Mar 2019; status: active, not recruiting.
02
Drugs
zanzalintinib
03
Conditions
solid tumorclear cell renal cell carcinoma (ccRCC)non-clear cell renal cell carcinoma (nccRCC)Hormone-Receptor-Positive Breast Cancermetastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03845166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03845166.